Successfully reported this slideshow.
Your SlideShare is downloading. ×

Fine-Tuning Biomarker Testing to Identify and Target RET Fusions as Uncommon But Actionable Genomic Alterations in NSCLC

Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad

Check these out next

1 of 75 Ad

Fine-Tuning Biomarker Testing to Identify and Target RET Fusions as Uncommon But Actionable Genomic Alterations in NSCLC

Download to read offline

Chair, Nathan A. Pennell, MD, PhD, FASCO, and Laura J. Tafe, MD, discuss NSCLC in this CME/MOC/CC/NCPD/CPE/IPCE activity titled “Fine-Tuning Biomarker Testing to Identify and Target RET Fusions as Uncommon But Actionable Genomic Alterations in NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC/NCPD/CPE/IPCE information, and to apply for credit, please visit us at https://bit.ly/3fwhuok. CME/MOC/CC/NCPD/CPE/IPCE credit will be available until January 29, 2024.

Chair, Nathan A. Pennell, MD, PhD, FASCO, and Laura J. Tafe, MD, discuss NSCLC in this CME/MOC/CC/NCPD/CPE/IPCE activity titled “Fine-Tuning Biomarker Testing to Identify and Target RET Fusions as Uncommon But Actionable Genomic Alterations in NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC/NCPD/CPE/IPCE information, and to apply for credit, please visit us at https://bit.ly/3fwhuok. CME/MOC/CC/NCPD/CPE/IPCE credit will be available until January 29, 2024.

Advertisement
Advertisement

More Related Content

More from PVI, PeerView Institute for Medical Education (20)

Recently uploaded (20)

Advertisement

×